Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone

   
Google
 
Web NewDrugInformation.com

Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone


Drug - Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone
The trade name of the product as shown on the labeling.

Dosage - SUSPENSION/DROPS; OPHTHALMIC
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Hydrocortisone; Neomycin Sulfate; Polymyxin B Sulfate
Multiple ingredients are in alphabetical order.

Strength - 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
The potency of the active ingredient(s), Hydrocortisone; Neomycin Sulfate; Polymyxin B Sulfate. May repeat for multiple part products.

Applicant - PHARMAFAIR
The firm name holding legal responsibility for Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 062623
The FDA assigned number to Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Sep 24, 1985
The date Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone is in. Format is RX, OTC, DISCN.

Applicant Full Name - Pharmafair Inc
The full name of the firm holding legal responsibility for the new application of Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone.

Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone


Cortisporin 1%;eq 3.5mg Base/ml;10,000 Units/ml Solution/drops; Otic
Neomycin And Polymyxin B Sulfates And Hydrocortisone 1%;eq 3.5mg Base/ml;10,000 Units/ml Solution/drops; Otic
Neomycin And Polymyxin B Sulfates And Hydrocortisone 1%;eq 3.5mg Base/ml;10,000 Units/ml Solution/drops; Otic
Neomycin And Polymyxin B Sulfates And Hydrocortisone 1%;eq 3.5mg Base/ml;10,000 Units/ml Solution/drops; Otic
Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone 1%;eq 3.5mg Base/ml;10,000 Units/ml Solution/drops; Otic
Otocort 1%;eq 3.5mg Base/ml;10,000 Units/ml Solution/drops; Otic
Cortisporin 1%;eq 3.5mg Base/ml;10,000 Units/ml Suspension/drops; Ophthalmic
Neomycin And Polymyxin B Sulfates And Hydrocortisone 1%;eq 3.5mg Base/ml;10,000 Units/ml Suspension/drops; Ophthalmic
Neomycin Sulfate-polymyxin B Sulfate-hydrocortisone 1%;eq 3.5mg Base/ml;10,000 Units/ml Suspension/drops; Ophthalmic
Neo-cort-dome 1%;eq 3.5mg Base/gm Cream; Topical

NewDrugInformation